
Graciela S AlarcÃ³n

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/91357/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
2	Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Annals of the Rheumatic Diseases, 2007, 66, 1168-1172.	0.9	428
3	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.9	391
4	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	1.9	370
5	Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis and Rheumatism, 2013, 65, 753-763.	6.7	357
6	Prognosis in systemic lupus erythematosus. Arthritis and Rheumatism, 1990, 33, 37-48.	6.7	323
7	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	12.8	314
8	Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort. Arthritis and Rheumatism, 2001, 45, 191-202.	6.7	299
9	Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events. Arthritis and Rheumatism, 2004, 50, 3947-3957.	6.7	273
10	Psychiatric diagnoses in patients with fibromyalgia are related to health care–seeking behavior rather than to illness. Arthritis and Rheumatism, 1996, 39, 436-445.	6.7	256
11	Cancer risk in systemic lupus: An updated international multi-centre cohort study. Journal of Autoimmunity, 2013, 42, 130-135.	6.5	249
12	Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis and Rheumatism, 1993, 36, 1196-1206.	6.7	239
13	Systemic lupus erythematosus in three ethnic groups: IX. Differences in damage accrual. Arthritis and Rheumatism, 2001, 44, 2797-2806.	6.7	230
14	A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis and Rheumatism, 2007, 57, 576-584.	6.7	228
15	Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. Arthritis and Rheumatism, 1998, 41, 1173-1180.	6.7	202
16	Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis and Rheumatism, 1993, 36, 329-335.	6.7	187
17	Antimalarial treatment may have a timeâ€dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis and Rheumatism, 2010, 62, 855-862.	6.7	177
18	Epidemiology of systemic lupus erythematosus. Expert Review of Clinical Immunology, 2017, 13, 799-814.	3.0	167

#	Article	IF	CITATIONS
19	Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population. Arthritis and Rheumatism, 2012, 64, 2669-2676.	6.7	163
20	Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis and Rheumatism, 2007, 56, 622-630.	6.7	147
21	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
22	Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis and Rheumatism, 2004, 51, 465-474.	6.7	141
23	Comparison of auranofin, methotreaxate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism, 1992, 35, 259-269.	6.7	139
24	Systemic lupus erythematosus in a multiethnic US cohort: Clinical features, course, and outcome in patients with late-onset disease. Arthritis and Rheumatism, 2006, 54, 1580-1587.	6.7	115
25	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and SjA¶gren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1290-1300.	5.6	114
26	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Annals of the Rheumatic Diseases, 2015, 74, 1019-1023.	0.9	100
27	Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology, 2009, 48, 817-822.	1.9	99
28	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	5.6	98
29	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq1 1 C Diseases, 2018, 77, 1549-1557.</i>	.784314 r	gBT ₉ Overlock
30	Time to Renal Disease and End-Stage Renal Disease in PROFILE: A Multiethnic Lupus Cohort. PLoS Medicine, 2006, 3, e396.	8.4	90
31	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Annals of the Rheumatic Diseases, 2017, 76, 2071-2074.	0.9	89
32	Analysis of autosomal genes reveals gene–sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, 694-699.	0.9	87
33	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
34	The IRF5–TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	2.9	74
35	Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis and Rheumatism, 2009, 61, 1179-1186.	6.7	71
36	Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian–European populations. Arthritis and Rheumatism, 2012, 64, 3687-3694.	6.7	70

#	Article	IF	CITATIONS
37	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
38	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70
39	Infections in Systemic Connective Tissue Diseases: Systemic Lupus Erythematosus, Scleroderma, and Polymyositis/Dermatomyositis. Infectious Disease Clinics of North America, 2006, 20, 849-875.	5.1	63
40	Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity. Arthritis and Rheumatism, 2004, 51, 73-77.	6.7	62
41	Impact of Race and Ethnicity in the Course and Outcome of Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2014, 40, 433-454.	1.9	58
42	Azathioprine versus d-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold. Arthritis and Rheumatism, 1984, 27, 721-727.	6.7	57
43	Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. Arthritis and Rheumatism, 2004, 51, 609-615.	6.7	56
44	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
45	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
46	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. American Journal of Epidemiology, 2015, 181, 406-421.	3.4	54
47	Psychosocial and health status variables independently predict health care seeking in fibromyalgia. Arthritis and Rheumatism, 2001, 45, 362-371.	6.7	52
48	Systemic lupus erythematosus in three ethnic groups: IV. Factors associated with self-reported functional outcome in a large cohort study. Arthritis and Rheumatism, 1999, 12, 256-266.	6.7	51
49	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
50	Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis and Rheumatism, 1993, 36, 1364-1369.	6.7	48
51	Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Current Rheumatology Reports, 2000, 2, 141-148.	4.7	48
52	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology, 2012, 51, 1293-1298.	1.9	46
53	Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. Expert Review of Clinical Immunology, 2018, 14, 915-931.	3.0	45
54	Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. Journal of Rheumatology, 2005, 32, 2150-5.	2.0	44

#	Article	IF	CITATIONS
55	Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Seminars in Arthritis and Rheumatism, 2016, 45, 675-683.	3.4	43
56	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Human Molecular Genetics, 2018, 27, 3813-3824.	2.9	43
57	Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis and Rheumatism, 1985, 28, 308-314.	6.7	42
58	African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Annals of the Rheumatic Diseases, 2007, 66, 618-622.	0.9	42
59	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
60	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.9	40
61	Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. Journal of the National Medical Association, 2007, 99, 1196-8.	0.8	40
62	Systemic Lupus Erythematosus in a Multiethnic US Cohort (LUMINA): LXI. Value of C-Reactive Protein as a Marker of Disease Activity and Damage. Journal of Rheumatology, 2008, 35, 2355-2358.	2.0	39
63	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	5.6	39
64	Nutrient intake patterns, body mass index, and vitamin levels in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1997, 10, 9-17.	6.7	37
65	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
66	Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. American Journal of Human Genetics, 2015, 96, 731-739.	6.2	36
67	A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	2.9	34
68	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
69	Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factorsdata from a multi-ethnic Latin American cohort. Rheumatology, 2014, 53, 1431-1438.	1.9	33
70	Abatacept for the treatment of systemic lupus erythematosus. Expert Opinion on Investigational Drugs, 2016, 25, 493-499.	4.1	33
71	Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues. Current Rheumatology Reports, 2010, 12, 237-249.	4.7	32
72	Pure red cell aplasia and protein-losing enteropathy in a patient with systemic lupus erythematosus. Arthritis and Rheumatism, 1985, 28, 1059-1061.	6.7	31

#	Article	IF	CITATIONS
73	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
74	Thrombosis in systemic lupus erythematosus: risk and protection. Expert Review of Cardiovascular Therapy, 2009, 7, 1541-1549.	1.5	30
75	Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus. Oncology, 2013, 85, 235-240.	1.9	30
76	The evolving concept of SLE comorbidities. Expert Review of Clinical Immunology, 2017, 13, 753-768.	3.0	30
77	Systemic lupus erythematosus in three ethnic groups: V. Acculturation, health-related attitudes and behaviors, and disease activity in Hispanic patients from the LUMINA Cohort. Arthritis and Rheumatism, 1999, 12, 267-276.	6.7	29
78	Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome. Current Review of Pain, 2000, 4, 148-157.	0.7	29
79	Molecular forms of IgA rheumatoid factor in serum and synovial fluid of patients with rheumatoid arthritis. Arthritis and Rheumatism, 1986, 29, 1194-1202.	6.7	28
80	Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology, 2010, 49, 1720-1725.	1.9	27
81	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27
82	Abnormal Regional Cerebral Blood Flow in the Caudate Nucleus Among Fibromyalgia Patients and Non-Patients Is Associated with Insidious Symptom Onset. Journal of Musculoskeletal Pain, 1999, 7, 285-292.	0.3	26
83	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	5.6	26
84	Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. RMD Open, 2020, 6, e001097.	3.8	26
85	Lupus risk variants in the PXK locus alter B-cell receptor internalization. Frontiers in Genetics, 2015, 5, 450.	2.3	25
86	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
87	Insufficiency fractures of the distal tibia misdiagnosed as cellulitis in three patients with rheumatoid arthritis. Arthritis and Rheumatism, 1991, 34, 912-915.	6.7	24
88	Health Care Seeking Behavior in Fibromyalgia:. Journal of Musculoskeletal Pain, 1994, 2, 79-87.	0.3	24
89	Systemic lupus erythematosus: The search for the ideal biomarker. Lupus, 2021, 30, 181-203.	1.6	24
90	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. Lupus Science and Medicine, 2021, 8, e000542.	2.7	24

#	Article	IF	CITATIONS
91	Lessons from LUMINA: a multiethnic US cohort. Lupus, 2008, 17, 971-976.	1.6	23
92	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	3.4	23
93	Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Annals of the Rheumatic Diseases, 2022, 81, 1260-1266.	0.9	23
94	Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort. Arthritis and Rheumatism, 2007, 57, 986-992.	6.7	22
95	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	3.4	22
96	Differential patterns of in vitro IgM rheumatoid factor synthesis in seronegative and seropositive rheumatoid arthritis. Arthritis and Rheumatism, 1982, 25, 150-155.	6.7	21
97	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
98	Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. Journal of Rheumatology, 2019, 46, 1299-1308.	2.0	21
99	DR antigens in systemic sclerosis: lack of clinical correlations. Tissue Antigens, 1985, 26, 156-158.	1.0	20
100	Better Healthâ€Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort. Arthritis Care and Research, 2020, 72, 1159-1162.	3.4	20
101	Measures of Fatigue in Patients With Rheumatic Diseases: A Critical Review. Arthritis Care and Research, 2020, 72, 369-409.	3.4	20
102	Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients. Clinical Rheumatology, 2017, 36, 845-852.	2.2	19
103	A comparison of the full and short versions of the arthritis impact measurement scales. Arthritis and Rheumatism, 1991, 4, 168-173.	6.7	17
104	Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. Rheumatology, 2016, 55, kev280.	1.9	17
105	Incomplete Systemic Lupus Erythematosus: Early Diagnosis or Overdiagnosis?. Arthritis Care and Research, 2016, 68, 285-287.	3.4	17
106	Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. RMD Open, 2019, 5, e000955.	3.8	17
107	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	5.6	17
108	Circulating naive and memory CD4 ⁺ T cells and metabolic syndrome in patients with systemic lupus erythematosus: data from a primarily Mestizo population. Rheumatology, 2015, 54, 1302-1307.	1.9	16

#	Article	IF	CITATIONS
109	Decreased <i>SMG7</i> expression associates with lupus-risk variants and elevated antinuclear antibody production. Annals of the Rheumatic Diseases, 2016, 75, 2007-2013.	0.9	16
110	Damage, Accelerated Atherosclerosis, and Mortality in Patients With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2007, 13, 350-353.	0.9	13
111	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	3.4	13
112	Applying the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Lupus Criteria to Patients From the LUMINA Cohort: Results From the Multiethnic, Multicenter US Cohort. Arthritis Care and Research, 2021, 73, 1451-1455.	3.4	13
113	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
114	LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort. Lupus Science and Medicine, 2022, 9, e000616.	2.7	12
115	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Seminars in Arthritis and Rheumatism, 2017, 47, 199-203.	3.4	11
116	ANCA-Associated Vasculitis in Latin America. Journal of Clinical Rheumatology, 2022, 28, 44-51.	0.9	11
117	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. Clinical Immunology, 2015, 161, 157-162.	3.2	10
118	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Annals of the Rheumatic Diseases, 2016, 75, 242-252.	0.9	10
119	Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. Clinical Rheumatology, 2019, 38, 2737-2746.	2.2	10
120	Global Rheumatology Research: Frontiers, Challenges, and Opportunities. Arthritis and Rheumatology, 2022, 74, 1-4.	5.6	10
121	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. Global Rheumatology, 0,	0.0	10
122	Methotrexate in Rheumatoid Arthritis. BioDrugs, 1997, 8, 164-175.	4.6	9
123	Rheumatoid arthritis in the indigenous qom population of Rosario, Argentina: aggressive and disabling disease with inadequate adherence to treatment in a community-based cohort study. Clinical Rheumatology, 2018, 37, 2323-2330.	2.2	9
124	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	3.4	9
125	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
126	Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatology, 2006, 1, 225-233.	0.2	8

#	Article	IF	CITATIONS
127	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
128	Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. Clinical Rheumatology, 2021, 40, 4725-4734.	2.2	8
129	Familial studies in human brucellosis. Tissue Antigens, 1985, 26, 77-79.	1.0	7
130	Treat to target in systemic lupus erythematosus: a commentary. Clinical Rheumatology, 2016, 35, 1903-1907.	2.2	7
131	Therapeutic Guidelines for Latin American Lupus Patients. Journal of Clinical Rheumatology, 2018, 24, 41-44.	0.9	7
132	Remission or low disease activity as a target in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, e3-e3.	0.9	7
133	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
134	Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort. Lupus Science and Medicine, 2022, 9, e000641.	2.7	7
135	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
136	Serum uric acid is associated with damage in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2020, 7, e000366.	2.7	6
137	Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. Lupus Science and Medicine, 2020, 7, e000419.	2.7	6
138	Issues in meta-analysis: An overview. Arthritis and Rheumatism, 1994, 7, 156-160.	6.7	5
139	Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort. Rheumatic Disease Clinics of North America, 2021, 47, 55-64.	1.9	5
140	Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. Journal of Clinical & Cellular Immunology, 2013, 04, 179.	1.5	5
141	Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. Lupus, 2022, 31, 105-109.	1.6	5
142	Association of Systemic Lupus International Collaborating Clinics Frailty Index With Damage in Systemic Lupus Erythematosus Patients: Results From a Multiethnic, Multicenter <scp>US</scp> Cohort of Patients With Lupus. Arthritis Care and Research, 2023, 75, 585-589.	3.4	5
143	Efficacy and safety of 10â€deazaaminopterin in the treatment of rheumatoid arthritis: A oneâ€year continuation, doubleâ€blind study. Arthritis and Rheumatism, 1992, 35, 1318-1321.	6.7	4
144	Systemic Lupus Erythematosus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6572-6581.	3.8	4

#	Article	IF	CITATIONS
145	Jaccoud's arthropathy in SLE: findings from a Latin American multiethnic population. Lupus Science and Medicine, 2019, 6, e000343.	2.7	4
146	B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1103-1110.	2.5	4
147	Medical Scientific Publications From Latin America. Journal of Clinical Rheumatology, 2019, 25, 157-158.	0.9	3
148	Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort. Clinical Rheumatology, 2019, 38, 1139-1146.	2.2	3
149	How well do the new classification criteria for SLE perform?. Nature Reviews Rheumatology, 2021, 17, 7-8.	8.0	3
150	Communityâ€Engaged Research to Address Health Disparities in Systemic Lupus Erythematosus. Arthritis Care and Research, 2021, 73, 305-307.	3.4	3
151	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	1.6	3
152	Health-Related Quality of Life and fatigue are associated with a higher work productivity impairment in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. Lupus, 2021, 30, 2157-2161.	1.6	3
153	Peripheral CD4+CD28null T-cells as predictors of damage inÂsystemic lupus erythematosus patients. Clinical and Experimental Rheumatology, 2018, 36, 1008-1013.	0.8	3
154	The PANLAR Rheumatology Prize for Latin American Rheumatologists. Journal of Clinical Rheumatology, 2014, 20, 94-95.	0.9	2
155	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	1.6	2
156	Interest on the internet for systemic lupus erythematosus: Analysis of Google Trends in Latin American countries. Lupus, 2021, 30, 1342-1346.	1.6	2
157	Performance of the 2017 American College of Rheumatology/European League Against Rheumatism Provisional Classification Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in a Peruvian Tertiary Care Center. Journal of Clinical Rheumatology, 2021, Publish Ahead of Print, .	0.9	2
158	Organ damage in systemic lupus erythematosus. Revista Colombiana De ReumatologÃa, 2021, 28, 66-81.	0.1	2
159	Systemic lupus erythematosus in three ethnic groups: V. Acculturation, healthâ€related attitudes and behaviors, and disease activity in Hispanic patients from the LUMINA Cohort. Arthritis and Rheumatism, 1999, 12, 267-276.	6.7	2
160	Relationship between care model and disease activity states and health-related quality of life in systemic lupus erythematosus patients. Lupus, 2022, 31, 110-115.	1.6	2
161	Combination of disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis A survey of alabama rheumatologists. Arthritis and Rheumatism, 1991, 4, 48-51.	6.7	1
162	Overrepresentation of Elderly Subjects in a Populationâ€Based Study of Antiphospholipid Syndrome: Comment on the Article by Duarteâ€GarcÃa et al. Arthritis and Rheumatology, 2019, 71, 1768-1769.	5.6	1

#	Article	IF	CITATIONS
163	SAT0212â€ASSOCIATION BETWEEN SELF-EFFICACY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		1
164	Response to: â€~Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg. Annals of the Rheumatic Diseases, 2019, 78, e120-e120.	0.9	1
165	Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. Lupus, 2020, 29, 1644-1649.	1.6	1
166	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus, 2020, 29, 1140-1145.	1.6	1
167	Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE―by Whittall Garcia et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-220994.	0.9	1
168	Systemic lupus erythematosus in three ethnic groups: IV. Factors associated with selfâ€reported functional outcome in a large cohort study. Arthritis and Rheumatism, 1999, 12, 256-266.	6.7	1
169	Correspondence on a€ 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis' by Joanna C Robson <i>et al</i> and †2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis'. Annals of the Rheumatic Diseases,	0.9	1
170	2023, 62, 6197-6197. CS-07â€Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
171	CS-23â€Remission and low disease activity state are associated with a better health-related quality of life in systemic lupus erythematosus in a primarily mestizo population. , 2018, , .		0
172	CS-13â€Remission and low disease activity state prevent hospitalizations and emergency room visits in systemic lupus erythematosus patients. , 2018, , .		0
173	Is Low Disease Activity Sufficient as a Target in Systemic Lupus Erythematosus? Comment on the Article by Petri et al. Arthritis and Rheumatology, 2018, 70, 2098-2099.	5.6	0
174	A Practical Roadmap for Writing of Medical Scientific Publications. Journal of Clinical Rheumatology, 2019, 25, 314-317.	0.9	0
175	289â€Comparison of ACR 1982/1997 and EULAR/ACR classification criteria for systemic lupus erythematosus in two multiethnic cohorts. , 2019, , .		0
176	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. Rheumatology, 2020, 59, e165-e168.	1.9	0
177	Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus. Lupus, 2021, 30, 096120332110203.	1.6	0
178	Preconception, pregnancy, and lactation in systemic lupus erythematosus patients. Revista Colombiana De ReumatologAa, 2021, 28, 156-156.	0.1	0
179	1704â€Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
180	A 2-phase screening process for patients with Wegener's granulomatosis: a pilot study. Journal of Rheumatology, 2003, 30, 2420-1.	2.0	0